Literature DB >> 31646114

Cardiovascular risk assessment and screening in diabetes.

Yanglu Zhao1.   

Abstract

Diabetes used to be considered as a coronary heart disease equivalence and universally classified high cardiovascular risk population. However increasing epidemiological evidence now indicates the heterogeneity of risk among the diabetic patients and imposes animportance of stratifying those with relative low-risk from high-risk ones. Despite the existing risk assessment tools, current cardivoascualr disease prevention guidelines fail to provide more detailed stratification strategies for patient with diabetes and expose them to either overtreatment or undertreatment. On the other hand, various screening modality, including novel biomarkers and subclinical asthrosclerosis scanning, including coronary calcium scanning, carotid intima-media thickness, myocardial perfusion imaging and coronary computed tomography angiography, have provided very promising usage is risk stratification. With better developed test techniques and more extensive evidence, these modalities may serve in standardized screening algorithm to improve the cardiovascular risk assessment of patients with diabetes and better instruct their individualized preventive therapy.
Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Keywords:  cardiovascular disease; diabetes; guidelines; risk assessment

Year:  2017        PMID: 31646114      PMCID: PMC6768525          DOI: 10.1097/XCE.0000000000000115

Source DB:  PubMed          Journal:  Cardiovasc Endocrinol        ISSN: 2162-688X


  50 in total

Review 1.  On the importance of global cardiovascular risk assessment in people with type 2 diabetes.

Authors:  Justin B Echouffo-Tcheugui; Andre P Kengne
Journal:  Prim Care Diabetes       Date:  2013-04-25       Impact factor: 2.459

2.  Evaluation of low-density lipoprotein particle number distribution in patients with type 2 diabetes mellitus with low-density lipoprotein cholesterol <50 mg/dl and non-high-density lipoprotein cholesterol <80 mg/dl.

Authors:  Hector Malave; Manuel Castro; Jaime Burkle; Szilard Voros; Thomas Dayspring; Robert Honigberg; Ray Pourfarzib
Journal:  Am J Cardiol       Date:  2012-05-22       Impact factor: 2.778

3.  Lipoprotein-associated phospholipase A2 (Lp-PLA2) and future risk of type 2 diabetes: results from the Cardiovascular Health Study.

Authors:  T L Nelson; M L Biggs; J R Kizer; M Cushman; J E Hokanson; C D Furberg; K J Mukamal
Journal:  J Clin Endocrinol Metab       Date:  2012-03-07       Impact factor: 5.958

Review 4.  Prediction models for the risk of cardiovascular disease in patients with type 2 diabetes: a systematic review.

Authors:  S van Dieren; J W J Beulens; A P Kengne; L M Peelen; G E H M Rutten; M Woodward; Y T van der Schouw; K G M Moons
Journal:  Heart       Date:  2011-12-18       Impact factor: 5.994

5.  Darapladib for preventing ischemic events in stable coronary heart disease.

Authors:  Harvey D White; Claes Held; Ralph Stewart; Elizabeth Tarka; Rebekkah Brown; Richard Y Davies; Andrzej Budaj; Robert A Harrington; P Gabriel Steg; Diego Ardissino; Paul W Armstrong; Alvaro Avezum; Philip E Aylward; Alfonso Bryce; Hong Chen; Ming-Fong Chen; Ramon Corbalan; Anthony J Dalby; Nicolas Danchin; Robbert J De Winter; Stefan Denchev; Rafael Diaz; Moses Elisaf; Marcus D Flather; Assen R Goudev; Christopher B Granger; Liliana Grinfeld; Judith S Hochman; Steen Husted; Hyo-Soo Kim; Wolfgang Koenig; Ales Linhart; Eva Lonn; José López-Sendón; Athanasios J Manolis; Emile R Mohler; José C Nicolau; Prem Pais; Alexander Parkhomenko; Terje R Pedersen; Daniel Pella; Marco A Ramos-Corrales; Mikhail Ruda; Mátyás Sereg; Saulat Siddique; Peter Sinnaeve; Peter Smith; Piyamitr Sritara; Henk P Swart; Rody G Sy; Tamio Teramoto; Hung-Fat Tse; David Watson; W Douglas Weaver; Robert Weiss; Margus Viigimaa; Dragos Vinereanu; Junren Zhu; Christopher P Cannon; Lars Wallentin
Journal:  N Engl J Med       Date:  2014-03-30       Impact factor: 91.245

6.  Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis.

Authors:  David Preiss; Sreenivasa Rao Kondapally Seshasai; Paul Welsh; Sabina A Murphy; Jennifer E Ho; David D Waters; David A DeMicco; Philip Barter; Christopher P Cannon; Marc S Sabatine; Eugene Braunwald; John J P Kastelein; James A de Lemos; Michael A Blazing; Terje R Pedersen; Matti J Tikkanen; Naveed Sattar; Kausik K Ray
Journal:  JAMA       Date:  2011-06-22       Impact factor: 56.272

7.  Lipoprotein(a) and risk of type 2 diabetes.

Authors:  Samia Mora; Pia R Kamstrup; Nader Rifai; Børge G Nordestgaard; Julie E Buring; Paul M Ridker
Journal:  Clin Chem       Date:  2010-05-28       Impact factor: 8.327

8.  General cardiovascular risk profile for use in primary care: the Framingham Heart Study.

Authors:  Ralph B D'Agostino; Ramachandran S Vasan; Michael J Pencina; Philip A Wolf; Mark Cobain; Joseph M Massaro; William B Kannel
Journal:  Circulation       Date:  2008-01-22       Impact factor: 29.690

Review 9.  Prognostic Value of Coronary Computed Tomography Angiography in Patients With Diabetes: A Meta-analysis.

Authors:  Csilla Celeng; Pál Maurovich-Horvat; Brian B Ghoshhajra; Béla Merkely; Tim Leiner; Richard A P Takx
Journal:  Diabetes Care       Date:  2016-07       Impact factor: 19.112

Review 10.  Comparative performance of diabetes-specific and general population-based cardiovascular risk assessment models in people with diabetes mellitus.

Authors:  J-B Echouffo-Tcheugui; A P Kengne
Journal:  Diabetes Metab       Date:  2013-09-27       Impact factor: 6.041

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.